Ignite Creation Date:
2024-05-06 @ 6:46 PM
Last Modification Date:
2024-10-26 @ 2:54 PM
Study NCT ID:
NCT05783570
Status:
RECRUITING
Last Update Posted:
2024-03-15
First Post:
2023-02-27
Brief Title:
To Evaluate the Safety Tolerability and Preliminary Efficacy of EU307
Sponsor:
Eutilex
Organization:
Eutilex
Study Overview
Official Title:
A Dose-escalation Single-arm Open-Label Phase 1 Study to Evaluate the Safety Tolerability and Preliminary Efficacy of EU307 Autologous Glypican 3 Targeted Chimeric Antigen Receptor T Cell Therapy in Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Who Have Failed Standard Therapy
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To Evaluate the Safety Tolerability and Preliminary Efficacy of EU307 Autologous Glypican 3 GPC3 Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy
Detailed Description:
A Dose-escalation Single-arm Open-Label Phase 1 Study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None